Ludwig企业使用6 mRNAs提交乳腺癌检测方法临时专利,计划在2024年重新命名为RevealiaTM。 Ludwig Enterprises files provisional patent for breast cancer detection method using six mRNAs, plans to rebrand as Revealia™ in 2024.
路德维格企业已经申请了 一种叫做"癌症中不同表现的 mRNAs"的 癌症检测新方法的临时专利权 Ludwig Enterprises has filed a provisional patent for a new cancer detection method called "mRNAs Differentially Expressed in Cancer." 这一技术综合分析了六毫RNA,表明乳腺癌的敏感性和特殊性有所提高。 This technique analyzes a combination of six mRNAs, showing improved sensitivity and specificity for breast cancer. 研究涉及来自40个美国医疗中心的3 300多个脸颊细胞样本。 The research involved over 3,300 cheek cell samples from 40 U.S. medical centers. 该公司计划在监管批准之前改名为RevealiaTM, 并打算在2024年发射该技术。 The company plans to rebrand as Revealia™, pending regulatory approvals, and aims to launch the technology in 2024.